Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Clin Exp Allergy. 2010 Apr;40(4):547-62. doi: 10.1111/j.1365-2222.2010.03483.x.
The airway mucosal surfaces are constantly exposed to inhaled particles that can be potentially toxic, infectious or allergenic and should elicit inflammatory changes. The proximal and distal air spaces, however, are normally infection and inflammation free due to a specialized interplay between cellular and molecular components of the pulmonary innate immune system. Surfactant protein D (SP-D) is an epithelial-cell-derived immune modulator that belongs to the small family of structurally related Ca(2+)-dependent C-type collagen-like lectins. While collectins can be detected in mucosal surfaces of various organs, SP-A and SP-D (the 'lung collectins') are constitutively expressed in the lung at high concentrations. Both proteins are considered important players of the pulmonary immune responses. Under normal conditions however, SP-A-/- mice display no pathological features in the lung. SP-D-/- mice, on the other hand, show chronic inflammatory alterations indicating a special importance of this molecule in regulating immune homeostasis and the function of the innate immune cells. Recent studies in our laboratory and others implied significant associations between changes in SP-D levels and the presence of airway inflammation both in animal models and patients raising a potential usefulness of this molecule as a disease biomarker. Research on wild-type and mutant recombinant molecules in vivo and in vitro showed that SP-D binds carbohydrates, lipids and nucleic acids with a broad spectrum specificity and initiates phagocytosis of inhaled pathogens as well as apoptotic cells. Investigations on gene-deficient and conditional over expressor mice in addition, provided evidence that SP-D directly modulates macrophage and dendritic cell function as well as T cell-dependent inflammatory events. Thus, SP-D has a unique, dual functional capacity to induce pathogen elimination on the one hand and control of pro-inflammatory mechanisms on the other, suggesting a potential suitability for therapeutic prevention and treatment of chronic airway inflammation without compromising the host defence function of the airways. This paper will review recent findings on the mechanisms of immune-protective function of SP-D in the lung.
气道黏膜表面不断暴露于吸入的颗粒中,这些颗粒可能具有潜在的毒性、传染性或变应原性,并应引起炎症变化。然而,由于肺部先天免疫系统的细胞和分子成分之间的特殊相互作用,近端和远端气腔通常不会受到感染和炎症的影响。表面活性蛋白 D(SP-D)是一种上皮细胞衍生的免疫调节剂,属于结构相关的 Ca(2+)依赖性 C 型胶原样凝集素的小家族。虽然在各种器官的黏膜表面都可以检测到集落形成蛋白,但 SP-A 和 SP-D(“肺集落形成蛋白”)在肺中以高浓度持续表达。这两种蛋白质都被认为是肺部免疫反应的重要参与者。然而,在正常情况下,SP-A-/-小鼠的肺部没有病理特征。另一方面,SP-D-/-小鼠表现出慢性炎症改变,表明该分子在调节免疫稳态和先天免疫细胞功能方面具有特殊重要性。我们实验室和其他实验室的最近研究表明,SP-D 水平的变化与气道炎症的存在之间存在显著关联,这不仅在动物模型中,而且在患者中都表明该分子作为疾病生物标志物具有潜在的用途。体内和体外对野生型和突变重组分子的研究表明,SP-D 具有广谱特异性结合碳水化合物、脂质和核酸,并启动对吸入病原体和凋亡细胞的吞噬作用。此外,对基因缺失和条件过表达小鼠的研究提供了证据表明,SP-D 直接调节巨噬细胞和树突状细胞功能以及 T 细胞依赖性炎症事件。因此,SP-D 具有独特的双重功能能力,一方面可以诱导病原体的消除,另一方面可以控制促炎机制,这表明它具有潜在的适合性,可以用于治疗慢性气道炎症,而不会损害气道的宿主防御功能。本文将综述 SP-D 在肺部的免疫保护功能的最新发现。